Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2359)

VOLUNTARY ANNOUNCEMENT

REMOVAL OF WUXI APPTEC AS A CHINESE MILITARY COMPANY UNDER THE SECTION 1260H LIST

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the "**Company**", "**WuXi AppTec**" or "**we**") on a voluntary basis.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, November 10, 2026

As of the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.

* *For identification purposes only*

REMOVAL OF WUXI APPTEC AS A CHINESE MILITARY COMPANY UNDER THE SECTION 1260H LIST

Reference is made to the Company's announcements dated June 9, 2026, June 11, 2026 (the "**June Announcements**") and August 9, 2026 (the "**August Announcement**"). As regards the designation by the United States Department of Defense (the "**DoD**") of the Company as a "Chinese military company" ("**CMC**") in the DoD's updated Section 1260H list on June 8, 2026 (United States time) (the "**1260H Designation**"), we stated in the June Announcements that WuXi AppTec would take immediate actions to challenge and correct this erroneous designation, and on June 11, 2026 (United States time), the Company filed a complaint at the United States District Court for the District of Columbia (the "**Court**") against the DoD. Subsequently, WuXi AppTec filed a motion for preliminary injunction with the Court on June 29, 2026 (United States time) seeking to enjoin the DoD from enforcing, implementing or taking any other action pursuant to the 1260H Designation. As stated in the August announcement, the Court held a hearing of our motion on July 22, 2026 (United States time) and issued a ruling on our motion for preliminary injunction on August 7, 2026 (United States time).

On November 9, 2026, we were made aware that the DoD decided to delist WuXi AppTec from the CMC list in accordance with Section 1260H. The Deputy Secretary of War has determined that WuXi AppTec should be removed from the DoD's updated Section 1260H List, in compliance with the order issued by the Court granting our motion for preliminary injunction.

This decision relieves the Company from further adverse consequences of the 1260H designation. We remain committed to serving our customers and enabling the lifesaving and life-improving medicines they make for patients.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.